Li Zhang, Feiyue Zhang, Gaofeng Li, Haifeng Liang
Department of Oncology, Gejiu People's Hospital, The Fifth Affiliated Hospital of Kunming Medical University, China.
Department of Oncology, Yuxi People's Hospital, The Sixth Affiliated Hospital of Kunming Medical University, China.
Transl Oncol. 2023 Jan;27:101563. doi: 10.1016/j.tranon.2022.101563. Epub 2022 Oct 14.
Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people's nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the most significant is that both of them are our enemies. The strategy to take the advantage of the virus to beat cancer cells is called Oncolytic virotherapy. When immunotherapy represented by immune checkpoint inhibitors has made remarkable breakthroughs in the clinical practice of lung cancer, the induction of antitumor immunity from immune cells gradually becomes a rapidly developing and promising strategy of cancer therapy. Oncolytic virotherapy is based on the same mechanisms that selectively kill tumor cells and induce systemic anti-tumor immunity, but still has a long way to go before it becomes a standard treatment for lung cancer. This article provides a comprehensive review of the latest progress in oncolytic virotherapy for lung cancer, including the specific mechanism of oncolytic virus therapy and the main types of oncolytic viruses, and the combination of oncolytic virotherapy and existing standard treatments. It aims to provide new insights and ideas on oncolytic virotherapy for lung cancer.
肺癌是全球范围内严重威胁人类健康的恶性肿瘤之一，而新冠病毒在冠状病毒大流行后成为了人们的噩梦。癌细胞和病毒之间存在太多相似之处，其中最显著的一点是它们都是我们的敌人。利用病毒来对抗癌细胞的策略被称为溶瘤病毒疗法。当以免疫检查点抑制剂为代表的免疫疗法在肺癌临床实践中取得显著突破时，从免疫细胞诱导抗肿瘤免疫逐渐成为一种快速发展且前景广阔的癌症治疗策略。溶瘤病毒疗法基于选择性杀死肿瘤细胞并诱导全身抗肿瘤免疫的相同机制，但在成为肺癌的标准治疗方法之前仍有很长的路要走。本文全面综述了肺癌溶瘤病毒疗法的最新进展，包括溶瘤病毒治疗的具体机制、溶瘤病毒的主要类型，以及溶瘤病毒疗法与现有标准治疗方法的联合应用。旨在为肺癌溶瘤病毒疗法提供新的见解和思路。
